These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33892273)

  • 1. Progress in developing MNK inhibitors.
    Jin X; Yu R; Wang X; Proud CG; Jiang T
    Eur J Med Chem; 2021 Jul; 219():113420. PubMed ID: 33892273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The MAP kinase-interacting kinases regulate cell migration, vimentin expression and eIF4E/CYFIP1 binding.
    Beggs JE; Tian S; Jones GG; Xie J; Iadevaia V; Jenei V; Thomas G; Proud CG
    Biochem J; 2015 Apr; 467(1):63-76. PubMed ID: 25588502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of Mitogen-activated Protein Kinase (MAPK)-interacting Kinase (MNK) Preferentially Affects Translation of mRNAs Containing Both a 5'-Terminal Cap and Hairpin.
    Korneeva NL; Song A; Gram H; Edens MA; Rhoads RE
    J Biol Chem; 2016 Feb; 291(7):3455-67. PubMed ID: 26668315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and activity of Mnk1 and Mnk2 selective inhibitors containing thieno[2,3-d]pyrimidine scaffold.
    Jin X; Merrett J; Tong S; Flower B; Xie J; Yu R; Tian S; Gao L; Zhao J; Wang X; Jiang T; Proud CG
    Eur J Med Chem; 2019 Jan; 162():735-751. PubMed ID: 30496989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors.
    Dreas A; Mikulski M; Milik M; Fabritius CH; Brzózka K; Rzymski T
    Curr Med Chem; 2017; 24(28):3025-3053. PubMed ID: 28164761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines.
    Ramalingam S; Gediya L; Kwegyir-Afful AK; Ramamurthy VP; Purushottamachar P; Mbatia H; Njar VC
    Oncotarget; 2014 Jan; 5(2):530-43. PubMed ID: 24504069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, Synthesis and Evaluation of Novel Phorbazole C Derivatives as MNK Inhibitors through Virtual High-Throughput Screening.
    Jin X; Li M; Qiu T; Yu R; Jiang T
    Mar Drugs; 2022 Jun; 20(7):. PubMed ID: 35877722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition.
    Reich SH; Sprengeler PA; Chiang GG; Appleman JR; Chen J; Clarine J; Eam B; Ernst JT; Han Q; Goel VK; Han EZR; Huang V; Hung INJ; Jemison A; Jessen KA; Molter J; Murphy D; Neal M; Parker GS; Shaghafi M; Sperry S; Staunton J; Stumpf CR; Thompson PA; Tran C; Webber SE; Wegerski CJ; Zheng H; Webster KR
    J Med Chem; 2018 Apr; 61(8):3516-3540. PubMed ID: 29526098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective and effective suppression of pancreatic cancer through MNK inhibition.
    Li H; Yao Y; Hao R; Long C
    Immunopharmacol Immunotoxicol; 2024 Oct; 46(5):651-661. PubMed ID: 39138614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
    Wang X; Yue P; Chan CB; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun SY
    Mol Cell Biol; 2007 Nov; 27(21):7405-13. PubMed ID: 17724079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
    Liu Y; Sun L; Su X; Guo S
    Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development.
    Ueda T; Watanabe-Fukunaga R; Fukuyama H; Nagata S; Fukunaga R
    Mol Cell Biol; 2004 Aug; 24(15):6539-49. PubMed ID: 15254222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MAP kinase-interacting kinases--emerging targets against cancer.
    Diab S; Kumarasiri M; Yu M; Teo T; Proud C; Milne R; Wang S
    Chem Biol; 2014 Apr; 21(4):441-452. PubMed ID: 24613018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E.
    Li Y; Yue P; Deng X; Ueda T; Fukunaga R; Khuri FR; Sun SY
    Neoplasia; 2010 Oct; 12(10):848-55. PubMed ID: 20927323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probing the binding mechanism of Mnk inhibitors by docking and molecular dynamics simulations.
    Kannan S; Poulsen A; Yang HY; Ho M; Ang SH; Eldwin TS; Jeyaraj DA; Chennamaneni LR; Liu B; Hill J; Verma CS; Nacro K
    Biochemistry; 2015 Jan; 54(1):32-46. PubMed ID: 25431995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Regulation of ZEB1 and EMT by MAPK-Interacting Protein Kinases (MNK) and eIF4E in Pancreatic Cancer.
    Kumar K; Chow CR; Ebine K; Arslan AD; Kwok B; Bentrem DJ; Eckerdt FD; Platanias LC; Munshi HG
    Mol Cancer Res; 2016 Feb; 14(2):216-27. PubMed ID: 26609108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of eukaryotic initiation factor 4E (eIF4E) phosphorylation by mitogen-activated protein kinase occurs through modulation of Mnk1-eIF4G interaction.
    Shveygert M; Kaiser C; Bradrick SS; Gromeier M
    Mol Cell Biol; 2010 Nov; 30(21):5160-7. PubMed ID: 20823271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylation of the mRNA cap-binding protein eIF4E and cancer.
    Yang X; Zhong W; Cao R
    Cell Signal; 2020 Sep; 73():109689. PubMed ID: 32535199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.
    Abdelaziz AM; Diab S; Islam S; Basnet SKC; Noll B; Li P; Mekonnen LB; Lu J; Albrecht H; Milne RW; Gerber C; Yu M; Wang S
    Med Chem; 2019; 15(6):602-623. PubMed ID: 30569866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mnk inhibitors: a patent review.
    Abdelaziz AM; Yu M; Wang S
    Pharm Pat Anal; 2021 Jan; 10(1):25-35. PubMed ID: 33441033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.